✦ LIBER ✦

Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study

✍ Scribed by Alan Menter; Tiffani K. Hamilton; Darryl P. Toth; Hoi M. Leung; Graham Wetherill; Brian Hennessey; Marvin Garovoy; Paul Kwon; David M. Pariser; (for the Efalizumab Study Group)

Book ID: 110878039
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 376 KB
Volume: 46
Category: Article
ISSN: 0011-9059
DOI: 10.1111/j.1365-4632.2007.03158.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and tolerability of efalizumab th

Safety and tolerability of efalizumab therapy: A phase IIIb open-label study including patients using concurrent topical or phototherapy or recently transitioning from nonbiologic systemic psoriasis therapies

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Safety and tolerability of efalizumab th

Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: Results of an open-label phase IIIb multicenter trial

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Efficacy of efalizumab for the treatment

Efficacy of efalizumab for the treatment of moderate to severe plaque psoriasis: A prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Safety of efalizumab for the treatment o

Safety of efalizumab for the treatment of moderate to severe plaque psoriasis: A prospective 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America

📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Transitioning psoriasis patients to adal

Transitioning psoriasis patients to adalimumab following a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Sleep quality and other patient-reported

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial

✍ Strober, B.E.; Sobell, J.M.; Duffin, K.C.; Bao, Y.; Guérin, A.; Yang, H.; Goldbl 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB